Kutatási jelek – Signal Engine

• Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemia. — Multiple myeloma
• Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC‑4a) — Endometrial cancer
• Characteristics of late recurrences after hepatectomy for perihilar cholangiocarcinoma: a single‑center cohort study — Cholangiocarcinoma
• Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer — NSCLC
• 2025 World Conference on Lung Cancer (WCLC): key news stories — SCLC
• Breakthrough: How radiation helps the immune system kill cancer — NSCLC
• Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy — NSCLC
• CRISPR breakthrough reverses chemotherapy resistance in lung cancer — NSCLC
• Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline — Multiple myeloma
• Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T — Multiple myeloma
• Current treatments, practical management, and emerging investigational therapies for myelofibrosis — Myelofibrosis
• Preoperative PET or PET/CT for malignant diagnosis of Gastrointestinal stromal tumors: a systematic review and meta-analysis — Gastrointestinal stromal tumor
• Real-World Data Reveals Underdiagnosis of SCLC-Associated LEMS — SCLC
• Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer — Pancreatic cancer
• This powerful drug combo cuts prostate cancer deaths by 40% — Prostate cancer
• How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care? — Glioblastoma
• Modulation of the cytoskeleton for cancer therapy — Colorectal cancer
• Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma — Nasopharyngeal carcinoma
• Cell therapy in sarcoma: current landscape and future directions — Acute lymphoblastic leukemia
• Hemairologic Malignancy Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma — Diffuse large B-cell lymphoma